Savitz Ryan, CFO and CBO of Dianthus Therapeutics ($DNTH), sold shares on the open market twice in the last year for a total of $1.6 million. His most recent sale occurred on December 4, 2025. These transactions rank 3,918th out of 11,678 insiders in the database, well below the average sale amount of $8.6 million across 6.4 transactions. Savitz Ryan made no open market purchases during this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 31, 2026 | Dianthus Therapeutics, Inc. /DE/ | $DNTH | Savitz Ryan | EVP, CFO & CBO | M | Stock Option (Right to Buy) | 40000 | $0.00 | 80,000.0000 | 42,876,015 | 33.33% | 0.09% |
| March 31, 2026 | Dianthus Therapeutics, Inc. /DE/ | $DNTH | Savitz Ryan | EVP, CFO & CBO | M | Common Stock | 74367 | $8.44 | 74,367.0000 | 42,876,015 | 9999.99% | 0.17% |
| March 31, 2026 | Dianthus Therapeutics, Inc. /DE/ | $DNTH | Savitz Ryan | EVP, CFO & CBO | M | Common Stock | 40000 | $17.88 | 114,367.0000 | 42,876,015 | 53.79% | 0.09% |
| March 31, 2026 | Dianthus Therapeutics, Inc. /DE/ | $DNTH | Savitz Ryan | EVP, CFO & CBO | S | Common Stock | 1390 | $78.33 | 112,977.0000 | 42,876,015 | 1.22% | 0.00% |
| March 31, 2026 | Dianthus Therapeutics, Inc. /DE/ | $DNTH | Savitz Ryan | EVP, CFO & CBO | S | Common Stock | 21825 | $78.86 | 91,152.0000 | 42,876,015 | 19.32% | 0.05% |
| March 31, 2026 | Dianthus Therapeutics, Inc. /DE/ | $DNTH | Savitz Ryan | EVP, CFO & CBO | S | Common Stock | 1485 | $80.25 | 89,667.0000 | 42,876,015 | 1.63% | 0.00% |
| March 31, 2026 | Dianthus Therapeutics, Inc. /DE/ | $DNTH | Savitz Ryan | EVP, CFO & CBO | S | Common Stock | 800 | $81.36 | 88,867.0000 | 42,876,015 | 0.89% | 0.00% |
| March 31, 2026 | Dianthus Therapeutics, Inc. /DE/ | $DNTH | Savitz Ryan | EVP, CFO & CBO | S | Common Stock | 2366 | $82.84 | 86,501.0000 | 42,876,015 | 2.66% | 0.01% |
| March 31, 2026 | Dianthus Therapeutics, Inc. /DE/ | $DNTH | Savitz Ryan | EVP, CFO & CBO | S | Common Stock | 59800 | $83.90 | 26,701.0000 | 42,876,015 | 69.13% | 0.14% |
| March 31, 2026 | Dianthus Therapeutics, Inc. /DE/ | $DNTH | Savitz Ryan | EVP, CFO & CBO | S | Common Stock | 19469 | $84.57 | 7,232.0000 | 42,876,015 | 72.91% | 0.05% |
| March 31, 2026 | Dianthus Therapeutics, Inc. /DE/ | $DNTH | Savitz Ryan | EVP, CFO & CBO | S | Common Stock | 7232 | $85.54 | 0.0000 | 42,876,015 | 100.00% | 0.02% |
| March 31, 2026 | Dianthus Therapeutics, Inc. /DE/ | $DNTH | Savitz Ryan | EVP, CFO & CBO | M | Stock Option (Right to Buy) | 74367 | $0.00 | 10,399.0000 | 42,876,015 | 87.73% | 0.17% |
| Feb. 3, 2026 | Dianthus Therapeutics, Inc. /DE/ | $DNTH | Savitz Ryan | EVP, CFO & CBO | A | Stock Option (Right to Buy) | 150000 | $0.00 | 150,000.0000 | 42,876,015 | 9999.99% | 0.35% |
| Dec. 4, 2025 | Dianthus Therapeutics, Inc. /DE/ | $DNTH | Savitz Ryan | CFO & CBO | M | Stock Option (Right to Buy) | 20000 | $0.00 | 84,766.0000 | 42,876,015 | 30.88% | 0.05% |
| Dec. 4, 2025 | Dianthus Therapeutics, Inc. /DE/ | $DNTH | Savitz Ryan | CFO & CBO | M | Common Stock | 20000 | $8.44 | 20,000.0000 | 42,876,015 | 9999.99% | 0.05% |
| Dec. 4, 2025 | Dianthus Therapeutics, Inc. /DE/ | $DNTH | Savitz Ryan | CFO & CBO | S | Common Stock | 20000 | $45.18 | 0.0000 | 42,876,015 | 100.00% | 0.05% |
| Sept. 23, 2025 | Dianthus Therapeutics, Inc. /DE/ | $DNTH | Savitz Ryan | CFO & CBO | A | Stock Option (Right to Buy) | 60000 | $0.00 | 60,000.0000 | 32,125,179 | 9999.99% | 0.19% |
| Sept. 9, 2025 | Dianthus Therapeutics, Inc. /DE/ | $DNTH | Savitz Ryan | CFO & CBO | M | Stock Option (Right to Buy) | 20000 | $0.00 | 104,766.0000 | 32,125,179 | 23.59% | 0.06% |
| Sept. 9, 2025 | Dianthus Therapeutics, Inc. /DE/ | $DNTH | Savitz Ryan | CFO & CBO | M | Common Stock | 20000 | $8.44 | 20,000.0000 | 32,125,179 | 9999.99% | 0.06% |
| Sept. 9, 2025 | Dianthus Therapeutics, Inc. /DE/ | $DNTH | Savitz Ryan | CFO & CBO | S | Common Stock | 20000 | $35.00 | 0.0000 | 32,125,179 | 100.00% | 0.06% |
| Feb. 3, 2025 | Dianthus Therapeutics, Inc. /DE/ | $DNTH | Savitz Ryan | CFO & CBO | A | Stock Option (Right to Buy) | 150000 | $0.00 | 150,000.0000 | 0 | 9999.99% | 0.00% |
| May 23, 2024 | Dianthus Therapeutics, Inc. /DE/ | $DNTH | Savitz Ryan | CFO & CBO | A | Stock Option (Right to Buy) | 100000 | $0.00 | 100,000.0000 | 0 | 9999.99% | 0.00% |
| Jan. 24, 2024 | Dianthus Therapeutics, Inc. /DE/ | $DNTH | Savitz Ryan | CHIEF FINANCIAL OFFICER | A | Stock Option (Right to Buy) | 120000 | $0.00 | 120,000.0000 | 0 | 9999.99% | 0.00% |